Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs).

被引：0
|
作者：
Sibon, David [1 ]
Cannas, Giovanna [2 ]
Barraco, Fiorenza [2 ]
Prebet, Thomas [3 ]
Vey, Norbert [4 ]
Banos, Anne [5 ]
Besson, Caroline [6 ]
Corm, Selim [7 ]
Blanc, Michel [7 ]
Slama, Borhane [8 ]
Perrier, Herve [2 ]
Fenaux, Pierre [9 ]
Wattel, Eric [2 ]
机构：
[1] GFM, Paris, France
[2] GFM, Lyon, France
[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[4] Hop Paoli Calmettes, Marseille, France
[5] GFM, Bayonne, France
[6] Univ Paris 11, CHU Bicetre, INSERM, U1012, Le Kremlin Bicetre, France
[7] GFM, Chambery, France
[8] GFM, Avignon, France
[9] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1632 / 1632
页数：1
相关论文
共 50 条
  • [21] Treatment With Imetelstat Provides Durable Transfusion Independence in Heavily Transfused Non-Del(5q) Lower-Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 14
  • [22] Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase
    Santini, Valeria
    Platzbecker, Uwe
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Zeidan, Amer
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S373 - S374
  • [23] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Erica Tsang
    Heather A. Leitch
    Annals of Hematology, 2016, 95 : 73 - 78
  • [24] Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
    Platzbecker, Uwe
    Komrokji, Rami S.
    Zeidan, Amer M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Jonasova, Anna
    Illmer, Thomas
    Sherman, Laurie
    Berry, Tymara
    Riggs, Jennifer
    Xia, Qi
    Navada, Shyamala
    Wan, Ying
    Huang, Fei
    Feller, Faye M.
    Santini, Valeria
    BLOOD, 2023, 142
  • [25] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang, Erica
    Leitch, Heather A.
    ANNALS OF HEMATOLOGY, 2016, 95 (01) : 73 - 78
  • [26] Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
    Sanchez-Garcia, Joaquin
    del Canizo, Consuelo
    Lorenzo, Ignacio
    Nomdedeu, Benet
    Luno, Elisa
    de Paz, Raquel
    Xicoy, Blanca
    Valcarcel, David
    Brunet, Salut
    Marco-Betes, Victor
    Garcia-Pintos, Marta
    Osorio, Santiago
    Tormo, Mar
    Bailen, Alicia
    Cervero, Carlos
    Ramos, Fernando
    Diez-Campelo, Maria
    Such, Esperanza
    Arrizabalaga, Beatriz
    Azaceta, Gemma
    Bargay, Joan
    Arilla, Maria J.
    Falantes, Jose
    Serrano-Lopez, Josefina
    Sanz, Guillermo F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (02) : 189 - 201
  • [27] Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes
    Cerchione, Claudio
    Alfinito, Fiorella
    Soriente, Ilaria
    D'Arco, Alfonso Maria
    Danise, Paolo
    Cerciello, Giuseppe
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S325
  • [28] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [29] Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?
    Shallis, Rory M.
    Zeidan, Amer M.
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2015 - 2017
  • [30] Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents
    Garcia-Manero, Guillermo
    Matsuno, Rayna K.
    McBride, Ali
    Mohammed, Hina
    Idryo, Danny
    Broome, Ronda
    Herriman, Autumn
    Johnson, Tiffany
    Wilkinson, Kristiana
    Schrag, Andrew
    Johanson, Colden
    Izano, Monika
    Makinde, Adeola
    Mukherjee, Sudipto
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : e283 - e292
12345